香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 GF SECURITIES CO., LTD. 廣發証券股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1776） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，廣發証券股份有限公司（「本公司」）在深圳 證券交易所網站( http://www.szse.cn )刊發的《廣發証券股份有限公司2024年面向專 業投資者公開發行短期公司債券（第七期）2025年兌付兌息及摘牌公告》。茲載列 如下，僅供參閱。 承董事會命 廣發証券股份有限公司 林傳輝 董事長 中國，廣州 2025年5月12日 广发证券股份有限公司 2024 年面向专业投资者公开发行短期公司债券（第 七期）（债券简称："24 广 D14"，债券代码：524020，以下简称"本期债券"） 将于 2025 年 5 月 14 日支付 2024 年 11 月 21 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 GF SECURITIES CO., LTD. 廣發証券股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1776） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，廣發証券股份有限公司（「本公司」）在深圳 證券交易所網站( http://www.szse.cn )及中國報章刊發的《廣發証券股份有限公司關 於召開2024年度股東大會的提示性公告》。茲載列如下，僅供參閱。 承董事會命 廣發証券股份有限公司 林傳輝 董事長 中國，廣州 2025年5月13日 於本公告日期，本公司董事會成員包括執行董事林傳輝先生、秦力先生、孫曉燕 女士及肖雪生先生；非執行董事李秀林先生、尚書志先生及郭敬誼先生；獨立非 執行董事梁碩玲女士、黎文靖先生、張闖先生及王大樹先生。 证券代码：000776 证券简称：广发证券 公告编号：2025-0 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 GF SECURITIES CO., LTD. 廣發証券股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1776） 於本公告日期，本公司董事會成員包括執行董事林傳輝先生、秦力先生、孫曉燕 女士及肖雪生先生；非執行董事李秀林先生、尚書志先生及郭敬誼先生；獨立非 執行董事梁碩玲女士、黎文靖先生、張闖先生及王大樹先生。 关于"25 广发 D4"证券账户及托管单元调整的公告 广发证券股份有限公司 2025 年面向专业投资者公开发行短期公 司债券(第三期)已完成了初始登记工作,证券代码"524159",证 券简称"25 广发 D4"。 在登记托管过程中,由于投资人内部沟通不畅,提交的初始登记 信息有误,现需向深圳证券交易所和中国证券登记结算有限责任公司 深圳分公司申请调整证券账户及托管单元。调整主要信息如下: | 证券代码 | 证券简称 | 托管单元号 | 账户名称 | 证券账户 | 调整的 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （股份代號：1776） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，廣發証券股份有限公司（「本公司」）在深圳 證券交易所網站( http://www.szse.cn )刊發的《招商證券股份有限公司關於廣發証券 股份有限公司2025年第三次臨時受託管理事務報告》。茲載列如下，僅供參閱。 承董事會命 廣發証券股份有限公司 林傳輝 董事長 GF SECURITIES CO., LTD. 廣發証券股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 中國，廣州 2025年5月9日 於本公告日期，本公司董事會成員包括執行董事林傳輝先生、秦力先生、孫曉燕 女士及肖雪生先生；非執行董事李秀林先生、尚書志先生及郭敬誼先生；獨立非 執行董事梁碩玲女士、黎文靖先生、張闖先生及王大樹先生。 债券简称：21 广发 04 债券代码：149500 债券简 ...

Core Viewpoint - In the first quarter of 2025, Langzi Co., Ltd. experienced a decline in overall revenue but showed improvements in net profit and gross margin in certain business segments [2][3]. Financial Performance Summary - The total revenue for the first quarter of 2025 was approximately 1.399 billion yuan, a year-on-year decrease of 7.77% [2]. - The gross margin was 59.72%, an increase of 0.61 percentage points compared to the same period last year [2]. - The net profit attributable to shareholders was about 95 million yuan, up 5.12% year-on-year [2]. - The net cash flow from operating activities was approximately 174 million yuan, down 23.43% year-on-year [2]. - Basic earnings per share were 0.2153 yuan, an increase of 5.13% year-on-year [2]. - As of March 31, 2025, total assets were approximately 8.004 billion yuan, a 0.41% increase from the end of the previous year [2]. Business Segment Performance - **Medical Aesthetics Segment**: Revenue was approximately 670 million yuan, a decrease of 9.22% year-on-year; gross profit was about 369 million yuan, down 8.58% year-on-year; net profit attributable to shareholders was approximately 38.21 million yuan, a decrease of 36.94% [3]. - **Women's Clothing Segment**: Revenue was approximately 504 million yuan, a decrease of 5.74% year-on-year; gross profit was about 325 million yuan, down 5.52% year-on-year; net profit attributable to shareholders was approximately 36.63 million yuan, an increase of 21.21% [3]. - **Infant and Child Segment**: Revenue was approximately 221 million yuan, a decrease of 8.52% year-on-year; gross profit was about 137 million yuan, with a gross margin of 62.28%, up 1.78% year-on-year; net profit was 492,800 yuan, down 72.23% [3]. Investor Communication Insights - Various medical aesthetics brands showed mixed performance in Q1 2025, with Milan Baiyu's revenue decreasing by 8.74% to approximately 302.62 million yuan, while Jingfu Medical's revenue increased by 1.13% to approximately 125.20 million yuan [4]. - The company operated 41 medical aesthetics institutions as of the end of Q1 2025, including 12 comprehensive hospitals and 29 outpatient departments and clinics [4]. - The total inventory for the women's clothing segment was approximately 646 million yuan, a decrease of 4.75% from the end of the previous year, indicating improved inventory structure [4].

截至月份: 2025年4月30日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 廣發証券股份有限公司 呈交日期: 2025年5月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01776 | 說明 | 廣發証券H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,701,796,200 | RMB | | 1 | RMB | | 1,701,796,200 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | | | 本月底結存 | | | 1,701,796,200 | RMB | | | 1 RMB | | 1,701,796,200 | | 2 ...

Group 1: 2024 Performance Overview - The coal sector's overall net profit excluding non-recurring items is expected to decline by 20% year-on-year, with an average ROE of approximately 10% [1] - The total profit of large coal enterprises is projected to be 604.6 billion yuan, a year-on-year decrease of 22.2% [1] - Key coal companies are expected to achieve a net profit attributable to shareholders of 157.3 billion yuan and a net profit excluding non-recurring items of 155.5 billion yuan, down 18.6% and 19.7% year-on-year, respectively [1] Group 2: 2024 Operational Overview - The total coal production of 28 key coal companies is estimated at 1.34 billion tons, a year-on-year increase of 2.0% [2] - The weighted average net profit per ton of coal is approximately 131 yuan, reflecting a year-on-year decline of 25% [2] - The weighted average coal price and cost are projected to decrease by 7% and remain stable, respectively [2] Group 3: Q1 2025 Performance Overview - The sector's profit is expected to decline by 27% year-on-year, with an average net profit margin of around 11% [3] - The total net profit attributable to shareholders for Q1 2025 is projected to be 31 billion yuan, down 27.3% year-on-year [3] - The average gross profit margin and net profit margin for Q1 2025 are expected to drop to 25% and 11%, respectively [3] Group 4: Q1 2025 Operational Overview - The coal production of 24 companies is expected to reach 304 million tons, a year-on-year increase of 5.7% [4] - The weighted average net profit per ton of coal is projected to decrease to 97 yuan, with coal prices and costs declining by 18% and 15%, respectively [4] - Some companies, such as Shaanxi Energy and Yancoal, are expected to maintain a net profit per ton exceeding 100 yuan [4] Group 5: Industry Outlook - Seasonal demand for thermal coal is expected to improve marginally after May, with expectations of increased industrial demand and reduced coal imports [5] - Coal prices are anticipated to gradually recover after inventory declines, despite a potential downward trend in the price center for 2025 [5] Group 6: Key Companies - Companies with stable profits and high dividends include Shaanxi Coal and China Shenhua [6] - Companies with low valuations and long-term growth potential include China Coal Energy and Yancoal [6] - Companies benefiting from positive demand expectations and low PB ratios include Huabei Mining and Shanxi Coking Coal [6]

Core Insights - The report from GF Securities highlights the increasing domestic competition in the general electronic testing and measurement instruments industry, driven by the intensifying US-China technological rivalry and the demand for new productive forces [1] - The global market for general electronic measurement instruments is expected to exceed 40 billion, with the Chinese market projected to reach 16 billion by 2024, indicating significant potential for domestic companies to increase their market share [1] - The current domestic market penetration rate is only 7%, suggesting a vast space for replacement and growth [1] Group 1: Market Dynamics - The general electronic measurement instruments include digital oscilloscopes, RF instruments, and waveform generators, with a low domestic penetration rate and high barriers to entry [1] - According to Frost & Sullivan, the domestic market share of key players like Puyuan Precision, Dingyang Technology, and Urit has increased from 3% to 7% from 2018 to 2024, indicating a gradual shift towards domestic alternatives [1] Group 2: Factors Supporting Growth - The combination of geopolitical tensions and the need for high-end product localization is driving a surge in domestic demand for high-end products [2] - Domestic companies are increasingly developing self-researched chips, which mitigates reliance on foreign suppliers and accelerates product iteration [2] - The established R&D teams and distribution channels of domestic firms are well-prepared for the implementation of domestic alternatives [2] Group 3: Industry Recovery - The industry has experienced a downturn for nearly three years, but signs of recovery are emerging, with a positive growth rate of around 5% expected by March 2025 [3] - The strong demand from high-end manufacturing sectors such as new energy, automotive, and semiconductors is driving the commercialization of domestic brands [3] - Domestic high-end products, such as 13GHz oscilloscopes and 50GHz spectrum analyzers, are increasingly meeting the needs of local industrial enterprises [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 重要提示 1、国泰创业板新能源交易型开放式指数证券投资基金（以下简称"本基金"）的募集已获中国证监会证 监许可【2024】1670号文准予注册募集。中国证监会对本基金募集的注册，并不表明其对本基金的投资 价值、市场前景和收益做出实质性判断或保证，也不表明投资于本基金没有风险。 2、本基金类别为股票型证券投资基金，运作方式为交易型开放式。 3、本基金的基金管理人为国泰基金管理有限公司（以下简称"本公司"），基金托管人为广发证券股份 有限公司，登记机构为中国证券登记结算有限责任公司。 4、本基金募集对象为符合法律法规规定的可投资于证券投资基金的个人投资者、机构投资者、合格境 外投资者以及法律法规或中国证监会允许购买证券投资基金的其他投资人。 5、本基金自2025年5月12日至2025年5月23日进行发售。投资者可选择网上现金认购、网下现金认购2种 方式（本基金暂不开通网下股票认购）。如深圳证券交易所对网上现金认购时间作出调整，本公司将作 出相应调整并及时公告。基金管理人可根据认购的情况适当调整募集时间，但最长不超过法定募集期 限，并予以公告。 6、本基金首次募集规 ...

Core Viewpoint - The listed securities firms in China are set to distribute a total of 38.7 billion yuan in cash dividends for the year-end of 2024, despite some firms experiencing profit declines [1][2]. Summary by Category Dividend Distribution - A total of 40 listed securities firms have announced their year-end dividend plans, with a combined cash dividend of 38.74 billion yuan for 2024 [2]. - Compared to 2023, the number of firms planning to distribute dividends remains unchanged, but the total amount has decreased by nearly 1.9 billion yuan [2]. - The overall cash dividends for 2024 are still higher than 2023 by 12.8 billion yuan due to increased mid-year and special dividends [2]. Performance and Dividend Policy - 17 firms have a cash dividend ratio exceeding 40%, which is an increase from 2023 [1]. - Approximately 70% of the firms maintain a cash dividend ratio of 30% or above annually [1]. - Notably, firms like Guotai Junan and CITIC Securities lead in proposed cash dividends, with amounts of 4.923 billion yuan and 4.15 billion yuan respectively [2]. Impact of Profit Declines - Despite a 40.8% decline in net profit, Guolian Minsheng Securities plans to distribute 3.18 billion yuan in cash dividends, indicating a focus on long-term shareholder value [3]. - Other firms, including Guojin Securities and Everbright Securities, also plan dividends despite underperforming, with cash dividend ratios below 30% [3]. Strategic Focus on Shareholder Returns - The industry is increasingly embedding cash dividend policies into company charters, committing to distribute at least 10% of available profits annually and 30% over any three consecutive years [6]. - Market participants emphasize the importance of balancing strategic development, performance growth, and shareholder returns, with an average dividend yield of 1.63% across 40 firms [7].